Nationwide Survey of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children in the United States

2016 ◽  
Vol 34 (2) ◽  
pp. 206-208 ◽  
Author(s):  
Yusuke Okubo ◽  
Kotaro Nochioka ◽  
Marcia A. Testa
Keyword(s):  
United States ◽  
Toxic Epidermal Necrolysis ◽  
Nationwide Survey ◽  
The United States ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

scholarly journals Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States

2017 ◽  
Vol 76 (5) ◽  
pp. 811-817.e4 ◽  
Author(s):  
Derek Y. Hsu ◽  
Joaquin Brieva ◽  
Nanette B. Silverberg ◽  
Amy S. Paller ◽  
Jonathan I. Silverberg
Keyword(s):  
United States ◽  
Toxic Epidermal Necrolysis ◽  
The United States ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Comparing the Accuracy of ABCD-10 and SCORTEN in Predicting the In-Hospital Mortality of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multi-Institutional Study from Central China

Dermatology ◽  
2021 ◽  
pp. 1-9
Author(s):  
Huinan Suo ◽  
Biling Jiang ◽  
Xiaoyan Sun ◽  
Jing Dong ◽  
Mahin Alamgir ◽  
...  
Keyword(s):  
United States ◽  
Hospital Mortality ◽  
Prediction Model ◽  
Toxic Epidermal Necrolysis ◽  
Goodness Of Fit ◽  
The United States ◽  
Central China ◽  
Stevens Johnson Syndrome ◽  
Risk Of Death ◽  
Johnson Syndrome

<b><i>Background:</i></b> The newly described ABCD-10 (age, bicarbonate, cancer, dialysis, 10% body surface area [BSA]) is a 5-item mortality prediction model for patients with Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN). It was developed in the United States, has at present been externally tested only in the United States, Spain, and Singapore, and remains to be validated in resource-restricted settings. We sought to compare the accuracy of ABCD-10 and Score of Toxic Epidermal Necrolysis (SCORTEN) in predicting in-hospital mortality in a cohort from central China. Due to disease progression affecting the accuracy of the prediction model during hospitalization, for example, higher predictive accuracy of SCORTEN based on parameters collected on day 3 of hospitalization, we also assessed the overall predictive value of ABCD-10 on days 1 and 3, respectively. <b><i>Methods:</i></b> A retrospective study was performed over a 10-year period (2010–2020) from 3 medical institutions in Wuhan. The performance of predictive models was assessed by both discrimination and calibration. Receiver-operating characteristic (ROC) curves, Hosmer-Lemeshow goodness-of-fit tests and calibration plots were used to evaluate the model discrimination and calibration. <b><i>Results:</i></b> Of 84 included patients, 11 (13.1%) did not survive. The discrimination power of ABCD-10 was not significantly different from that of SCORTEN (area under the curve: day 1, <i>p</i> &#x3e; 0.05; day 3, <i>p</i> &#x3e; 0.05). Although the calibration of ABCD-10 was good, it was inferior to SCORTEN as it underestimated total mortality (Hosmer-Lemeshow goodness-of-fit test: day 1, <i>p</i> = 0.17 vs. <i>p</i> = 0.63; day 3, <i>p</i> = 0.35 vs. <i>p</i> = 0.93). Besides, the performance of ABCD-10 was slightly better on day 3 relative to day 1. During hospitalization, bacteremia developed in 21 (25.0%) patients, which was associated with a higher risk of death in our cohort (odds ratio, 22.88; 95% CI, 4.38–119.40; <i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> ABCD-10 showed acceptable overall performance, but revealed mortality underestimation and was inferior to the performance of SCORTEN. In consistence with SCORTEN, ABCD-10 was a better model when using values collected at day 3 of hospitalization relative to day 1.

scholarly journals Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States

2018 ◽  
Vol 138 (11) ◽  
pp. 2315-2321 ◽  
Author(s):  
Robert G. Micheletti ◽  
Zelma Chiesa-Fuxench ◽  
Megan H. Noe ◽  
Sasha Stephen ◽  
Maria Aleshin ◽  
...  
Keyword(s):  
United States ◽  
Retrospective Study ◽  
Toxic Epidermal Necrolysis ◽  
The United States ◽  
Adult Patients ◽  
Stevens Johnson Syndrome ◽  
Johnson Syndrome

Warning against long-acting sulphonamides

1966 ◽  
Vol 4 (4) ◽  
pp. 13-13
Keyword(s):  
United States ◽  
Mortality Rate ◽  
Erythema Multiforme ◽  
The United States ◽  
Stevens Johnson Syndrome ◽  
Warning Letter ◽  
Johnson Syndrome ◽  
The Us ◽  
Mucous Membranes ◽  
Long Acting

Last month the US Food and Drug Administration required American manufacturers of long-acting sulphonamides (sulphamethoxypyridazine, Lederkyn - Lederle and Midicel - PD; sulphadimethoxine - Madribon - Roche) to warn prescribers that in rare cases the Stevens-Johnson syndrome may develop as a severe and sometimes fatal side effect. This syndrome is a type of erythema multiforme in which large blisters appear on the skin and especially on the mucous membranes. The manufacturers were also to advise doctors ‘to consider prescribing short-acting sulphonamides first because they are effective for most of the same conditions’. The three drug firms concerned accordingly sent a joint warning letter to all doctors, pointing out that the Stevens-Johnson syndrome is a serious complication with a mortality rate of about 25%. So far 116 cases of this syndrome have been reported in association with the use of long-acting sulphonamides, most of them in the United States. Almost two thirds of the patients were children.

Sign in / Sign up

Export Citation Format

Share Document